Precision Oncology Liquid Biopsy

About Cambridge Nucleomics

Cambridge Nucleomics is pioneering a novel diagnostic platform using soluble nanoarrays and nanopore detection to quantify nucleic acids with unprecedented speed and multiplexing. Its lead program focuses on a one-hour point-of-care test for sepsis pathogen ID and antimicrobial resistance profiling, aiming to guide therapy within the critical 'golden hour'. The company, led by a team with strong scientific and commercial diagnostics expertise, is positioned to address major bottlenecks in molecular diagnostics by simplifying workflows and enabling rapid, decentralized testing.

Therapeutic Areas